

Pablo A Ureña-Torres

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/840807/publications.pdf>

Version: 2024-02-01

63
papers

2,518
citations

218677

26
h-index

206112

48
g-index

70
all docs

70
docs citations

70
times ranked

2569
citing authors

#	ARTICLE	IF	CITATIONS
1	2009 EANM parathyroid guidelines. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1201-1216.	6.4	272
2	Fractures in patients with CKD diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation. Kidney International, 2017, 92, 1343-1355.	5.2	151
3	Bone mineral density, biochemical markers and skeletal fractures in haemodialysis patients. Nephrology Dialysis Transplantation, 2003, 18, 2325-2331.	0.7	144
4	The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure. Kidney International, 1994, 45, 605-611.	5.2	134
5	Bone: a new endocrine organ at the heart of chronic kidney disease and mineral and bone disorders. Lancet Diabetes and Endocrinology, the, 2014, 2, 427-436.	11.4	125
6	Klotho: An antiaging protein involved in mineral and vitamin D metabolism. Kidney International, 2007, 71, 730-737.	5.2	118
7	Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?. Nephrology Dialysis Transplantation, 2014, 29, 1815-1820.	0.7	103
8	Adynamic Bone Disease: From Bone to Vessels in Chronic Kidney Disease. Seminars in Nephrology, 2014, 34, 626-640.	1.6	101
9	Association of Kidney Function, Vitamin D Deficiency, and Circulating Markers of Mineral and Bone Disorders in CKD. American Journal of Kidney Diseases, 2011, 58, 544-553.	1.9	97
10	Cinacalcet and achievement of the NKF/K-DOQITM recommended target values for bone and mineral metabolism in real-world clinical practice—the ECHO observational study. Nephrology Dialysis Transplantation, 2009, 24, 2852-2859.	0.7	89
11	Cinacalcet HCl: A Novel Treatment for Secondary Hyperparathyroidism Caused by Chronic Kidney Disease. , 2006, 16, 253-258.		58
12	When, How, and Why a Bone Biopsy Should Be Performed in Patients With Chronic Kidney Disease. Seminars in Nephrology, 2014, 34, 612-625.	1.6	53
13	Pro: Cardiovascular calcifications are clinically relevant. Nephrology Dialysis Transplantation, 2015, 30, 345-351.	0.7	53
14	Recent findings in phosphate homeostasis. Current Opinion in Nephrology and Hypertension, 2005, 14, 318-324.	2.0	52
15	Lack of evidence does not justify neglect: how can we address unmet medical needs in calciphylaxis?. Nephrology Dialysis Transplantation, 2016, 31, 1211-1219.	0.7	52
16	Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 161-174.	4.5	52
17	Alkaline Phosphatases in the Complex Chronic Kidney Disease-Mineral and Bone Disorders. Calcified Tissue International, 2018, 103, 111-124.	3.1	45
18	Relation Between Circulating Levels of 25(OH) Vitamin D and Parathyroid Hormone in Chronic Kidney Disease: Quest for a Threshold. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2922-2928.	3.6	44

#	ARTICLE	IF	CITATIONS
19	Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons. <i>Journal of Clinical Medicine</i> , 2019, 8, 287.	2.4	40
20	The need for reliable serum parathyroid hormone measurements. <i>Kidney International</i> , 2006, 70, 240-243.	5.2	36
21	Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 1241-1254.	0.7	36
22	Randomized Clinical Trial of Sevelamer Carbonate on Serum Klotho and Fibroblast Growth Factor 23 in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1930-1940.	4.5	35
23	Osteoporosis, densidad mineral \bar{A}^3 sea y complejo CKD-MBD (I): consideraciones diagn \bar{A}^3 sticas. <i>Nefrología</i> , 2018, 38, 476-490.	0.4	33
24	Parathyroid scintigraphy findings in chronic kidney disease patients with recurrent hyperparathyroidism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 623-634.	6.4	31
25	Three feedback loops precisely regulating serum phosphate concentration. <i>Kidney International</i> , 2011, 80, 443-445.	5.2	30
26	Novel insights into parathyroid hormone: report of The Parathyroid Day in Chronic Kidney Disease. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 269-280.	2.9	29
27	Short-term effects of parathyroidectomy on plasma biochemistry in chronic uremia. <i>Kidney International</i> , 1989, 36, 120-126.	5.2	27
28	Iron-based phosphate binders: do they offer advantages over currently available phosphate binders?. <i>CKJ: Clinical Kidney Journal</i> , 2015, 8, 161-167.	2.9	27
29	Evaluation of fracture risk in chronic kidney disease. <i>Journal of Nephrology</i> , 2017, 30, 653-661.	2.0	27
30	Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial. <i>BMC Nephrology</i> , 2014, 15, 71.	1.8	26
31	Bone, inflammation and chronic kidney disease. <i>Clinica Chimica Acta</i> , 2020, 506, 236-240.	1.1	26
32	The Non-invasive Diagnosis of Bone Disorders in CKD. <i>Calcified Tissue International</i> , 2021, 108, 512-527.	3.1	26
33	One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1769-1778.	0.7	25
34	Osteoporosis, densidad mineral \bar{A}^3 sea y complejo CKD-MBD (II): implicaciones terap \bar{A}^3 uticas. <i>Nefrología</i> , 2019, 39, 227-242.	0.4	24
35	Klotho Gene, Phosphocalcic Metabolism, and Survival in Dialysis. , 2009, 19, 50-56.		23
36	Clinical experience with cinacalcet HCl. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, v27-v33.	0.7	22

#	ARTICLE	IF	CITATIONS
37	Evidence in chronic kidney disease—“mineral and bone disorder guidelines: is it time to treat or time to wait?. CKJ: Clinical Kidney Journal, 2020, 13, 513-521.	2.9	22
38	Pharmacologic Role of Vitamin D Natural Products. Current Vascular Pharmacology, 2014, 12, 278-285.	1.7	22
39	The risk of medically uncontrolled secondary hyperparathyroidism depends on parathyroid hormone levels at haemodialysis initiation. Nephrology Dialysis Transplantation, 2021, 36, 160-169.	0.7	19
40	Magnesium-based interventions for normal kidney function and chronic kidney disease. Magnesium Research, 2016, 29, 126-140.	0.5	18
41	Calcificaciones cardiovasculares en la enfermedad renal cr�nica: Potenciales implicaciones terap�uticas. Nefrologia, 2016, 36, 597-608.	0.4	18
42	New Therapies for Uremic Secondary Hyperparathyroidism. , 2006, 16, 87-99.		17
43	The Effect of Sevelamer on Serum Levels of Gut-Derived Uremic Toxins: Results from In Vitro Experiments and A Multicenter, Double-Blind, Placebo-Controlled, Randomized Clinical Trial. Toxins, 2019, 11, 279.	3.4	17
44	Cardiovascular calcifications in chronic kidney disease: Potential therapeutic implications. Nefrologia, 2016, 36, 597-608.	0.4	15
45	English—“Latin nomenclature conundrum: should we use kidneylogy, kidneylogist?. Kidney International, 2020, 98, 1352-1353.	5.2	15
46	Detecci�n de las calcificaciones cardiovasculares: �una herramienta �til para el nefr�logo?. Nefrologia, 2016, 36, 587-596.	0.4	12
47	Osteoporosis, bone mineral density and CKD—“MBD complex (I): Diagnostic considerations. Nefrologia, 2018, 38, 476-490.	0.4	12
48	Longitudinal Bone Loss Occurs at the Radius in CKD. Kidney International Reports, 2021, 6, 1525-1536.	0.8	8
49	Los ri�ones tambi�n hablan espa�ol. Nefrologia, 2021, 41, 225-226.	0.4	8
50	The Use of Imaging Techniques in Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBD)—“A Systematic Review. Diagnostics, 2021, 11, 772.	2.6	7
51	Opponent's comments. Nephrology Dialysis Transplantation, 2015, 30, 357-357.	0.7	6
52	Feasible Low-Phosphorus Dietary Patterns in Maintenance Hemodialysis Patients: Need for Original Research. Kidney International Reports, 2020, 5, 1845-1847.	0.8	5
53	Cortical Bone Microarchitecture in Dialysis Patients. American Journal of Nephrology, 2020, 51, 833-838.	3.1	4
54	Los ri�ones tambi�n hablan espa�ol: iniciativas hacia la estandarizaci�n de nuestra nomenclatura nefrol�gica. Nefrologia, 2022, 42, 223-232.	0.4	4

#	ARTICLE	IF	CITATIONS
55	Bone Fragility in Chronic Kidney Disease Stage 3 to 5: The Use of Vitamin D Supplementation. <i>Metabolites</i> , 2022, 12, 266.	2.9	3
56	A Novel Heterozygous Deletion Variant in KLOTTHO Gene Leading to Haploinsufficiency and Impairment of Fibroblast Growth Factor 23 Signaling Pathway. <i>Journal of Clinical Medicine</i> , 2019, 8, 500.	2.4	2
57	Not all hyperphosphataemias should be treated. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1077-1079.	0.7	2
58	Citric Acid-Containing Dialysate and Survival Rate in the Dialysis Outcomes and Practice Patterns Study. <i>Kidney360</i> , 2021, 2, 666-673.	2.1	2
59	Relation Between PTH and Biochemical Markers of MBD. , 2020, , 103-116.		1
60	The "FIFTY SHADOWS" of the RALES Trial: Lessons about the Potential Risk of Dietary Potassium Supplementation in Patients with Chronic Kidney Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 3970.	2.4	1
61	The Authors Reply. <i>Kidney International</i> , 2018, 93, 1248-1249.	5.2	0
62	A loosening prosthesis in a dialysis patient. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 897-899.	2.9	0
63	MO900: Diuretic Prescription Patterns in Haemodialysis Patients: International Variation Reported in the Dopps. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.7	0